Cegedim

<div class="infobox">
<div class="infobox-header">Cegedim SA</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>CGDM.PA (Euronext Paris)</td></tr>
<tr><th>Headquarters</th><td>Boulogne-Billancourt, France</td></tr>
<tr><th>Founded</th><td>1969</td></tr>
<tr><th>Revenue (2024)</th><td>€611M</td></tr>
<tr><th>Employees</th><td>~4,000</td></tr>
<tr><th>CEO</th><td>Laurent Schaller (since 2023)</td></tr>
<tr><th>Market Cap</th><td>~€650M (2024)</td></tr>
</table>
</div>
</div>

Overview

<div class="infobox">
<div class="infobox-header">Cegedim SA</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>CGDM.PA (Euronext Paris)</td></tr>
<tr><th>Headquarters</th><td>Boulogne-Billancourt, France</td></tr>
<tr><th>Founded</th><td>1969</td></tr>
<tr><th>Revenue (2024)</th><td>€611M</td></tr>
<tr><th>Employees</th><td>~4,000</td></tr>
<tr><th>CEO</th><td>Laurent Schaller (since 2023)</td></tr>
<tr><th>Market Cap</th><td>~€650M (2024)</td></tr>
</table>
</div>
</div>

Overview

Cegedim is a French healthcare software and data analytics company headquartered in Boulogne-Billancourt, France. Founded in 1969, the company provides real-world data (RWD), electronic health records (EHR), and analytics solutions primarily focused on the European market["@cegedim_about"]. Cegedim serves pharmaceutical companies, healthcare providers, insurers, and researchers conducting neurodegenerative disease research across Europe.

The company operates through three main divisions: Cegedim Health Data (real-world data and analytics), Cegedim Healthcare Software (EHR and practice management), and Cegedim Insurance (insurance software). Cegedim is particularly notable for its ownership of THIN (The Health Improvement Network), one of Europe's largest primary care electronic health record databases["@thin_database"].

Real-World Data Services

THIN Database (The Health Improvement Network)

THIN is Cegedim's flagship real-world data product, representing one of the largest primary care EHR databases in Europe with data from over 40 million patients across multiple countries[@thin_validation]:

Database Characteristics:

• Coverage: Over 2,500 general practitioner practices across the UK, France, Spain, Germany, Italy, and the Netherlands
• Historical Depth: Patient records spanning 20+ years (since 1995)
• Patient Population: Representative of general population demographics
• Data Types: Consultations, diagnoses, prescriptions, laboratory results, referrals, clinical measurements
• Longitudinal Follow-up: Average of 7 years per patient

• Incidence and prevalence studies for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders[@parkinson_thin][@dementia_epidemiology]
• Treatment pattern analysis and medication adherence studies[@prescribing_patterns_ad]
• Disease progression and comorbidity mapping[@comorbidity_ad]
• Healthcare resource utilization and cost-of-illness studies[@healthcare_costs]
• Pharmacovigilance and drug safety monitoring[@methodological_quality]

European Healthcare Data Assets

Beyond THIN, Cegedim maintains additional healthcare databases[@cegedim_health]:

• Primary Care Data: EHR data from European general practitioners in multiple countries
• Pharmacy Data: Prescription and dispensing data across EU countries
• Hospital Data: Secondary care and inpatient records (selected markets)
• Cross-Border Coverage: Multi-country data for pan-European studies
• Specialty Registries: Disease-specific registries and specialty databases

Neurodegenerative Disease Research Capabilities

Alzheimer's Disease Research

Cegedim's databases support comprehensive AD research programs[@european_ad_cohorts][@rwe_neurodegeneration]:

Epidemiological Studies:

• Incidence and prevalence estimation across European populations
• Risk factor identification and stratification
• Disease subtype classification (early-onset vs. late-onset)
• Geographic variation analysis

• Cholinesterase inhibitor utilization patterns
• Real-world effectiveness of approved therapies
• Medication adherence and persistence
• Polypharmacy and drug interactions in dementia

• Resource utilization and costs analysis
• Care pathway optimization studies
• Quality of life and functional outcomes
• Burden on caregivers and healthcare systems

Parkinson's Disease Research

The THIN database has been extensively used for PD research[@parkinson_thin][@treatment_patterns]:

• Population-based incidence and prevalence estimation
• Motor and non-motor symptom documentation
• Treatment patterns: dopamine agonists, MAO-B inhibitors, levodopa
• Long-term outcomes and disease progression
• Neuropsychiatric complications and management

Related Neurodegenerative Disorders

Cegedim supports research on:

• Vascular dementia and mixed dementia subtypes
• Lewy body dementia and [dementia with Lewy bodies](/diseases/dementia-lewy-bodies)
• Frontotemporal dementia and related tauopathies
• Progressive supranuclear palsy and [corticobasal syndrome](/diseases/corticobasal-syndrome)
• Multiple system atrophy and other atypical parkinsonisms

Software Solutions

Healthcare IT Solutions

Cegedim provides a comprehensive suite of healthcare software[@cegedim_health]:

For Physicians:

• EHR Systems: Electronic health record software for primary care and specialty practices
• Practice Management: Appointment scheduling, billing, and administrative functions
• Prescribing Tools: Computerized physician order entry with drug interaction checking
• Telehealth Integration: Video consultation and remote patient monitoring platforms

• Pharmacy Management: Dispensing, inventory, and workflow management
• Clinical Services: Medication therapy management and adherence monitoring

• Hospital Information Systems: Integrated patient data management
• Laboratory Information Systems: Test ordering and result management
• Radiology Systems: Imaging workflow and storage

Data Analytics Platforms

Cegedim Analytics Solutions:

• Cohort Builder: Visual tool for patient cohort identification
• Population Explorer: Interactive dashboards for disease surveillance
• Comparative Analytics: Cross-country and cross-practice benchmarking
• Predictive Models: Risk stratification and outcome prediction
• Custom Analytics: Bespoke analysis and study support

Market Position and Competitive Landscape

Geographic Focus

Cegedim's primary markets include[@cegedim_about]:

• France: Largest market, headquarters location, strong EHR presence
• United Kingdom: THIN database primary data source, strong research presence
• Germany: Growing presence, healthcare software expansion
• Belgium: Data and software operations
• Spain: Southern European data coverage
• Italy: Emerging market
• Expansion Markets: Eastern European markets under development

Competitive Landscape

Cegedim competes with global and regional players in healthcare data and analytics:

| Competitor | Strengths | Cegedim Differentiation |
|------------|-----------|------------------------|
| IQVIA | Global scale, US data dominance | European primary care focus |
| Optum (UnitedHealth) | US-centric, integrated EHR | European coverage |
| Cerner/Oracle | Hospital systems | Primary care focus |
| Epic Systems | US hospital dominance | European market presence |
| PHMR | European RWE expertise | THIN data uniqueness |

Cegedim's Competitive Advantages:

• Unique primary care database with longitudinal patient data
• European regulatory expertise and data governance
• Direct GP relationships and data partnerships
• Integrated software + data offerings
• Established research methodology and validation[@data_quality]

Business Model and Revenue

Revenue Streams

Cegedim generates revenue through multiple channels:

Financial Performance (2024)

• Revenue: €611 million (2024)
• Segment Mix: Healthcare Data (~35%), Healthcare Software (~40%), Insurance (~25%)
• Geographic Mix: France (~45%), UK (~30%), Rest of Europe (~25%)
• Growth Drivers: RWE demand, digital health, European data regulations

Regulatory and Data Governance

Data Privacy Compliance

Cegedim maintains rigorous data governance frameworks:

• GDPR Compliance: Full adherence to EU General Data Protection Regulation
• Ethics Committee Approval: All research protocols require ethics review
• Data Anonymization: De-identification and aggregation protocols
• Data Protection Impact Assessments: Formal DPIA for all data processing
• Information Security: ISO 27001 certification and regular audits

Data Quality Standards

THIN database maintains established quality standards[@thin_validation][@data_quality]:

• Data Validation: Cross-sectional and longitudinal checks
• Recording Quality: GP training and feedback programs
• Linkage Capabilities: Safe havens for data linkage research
• Methodological Support: Publications and validation studies

Strategic Partnerships and Clients

Pharmaceutical Company Partnerships

Cegedim serves major pharmaceutical companies in neurodegenerative disease:

• Global pharma companies (top 20)
• Specialty pharma focused on CNS disorders
• Generic manufacturers
• Biotechnology companies

Academic Collaborations

Research collaborations with:

• University research teams
• National health services
• Disease registries
• Research consortia

Industry Trends and Future Outlook

Growth Drivers

Positive Trends:

• Increasing regulatory emphasis on real-world evidence
• Post-marketing surveillance requirements
• Value-based healthcare adoption
• Digital health integration
• Precision medicine initiatives

• Competition from US data vendors
• Regulatory complexity across EU countries
• Data quality and standardization
• GP engagement and data contribution

Emerging Focus Areas

Cegedim is expanding into:

• Digital Health Integration: Wearable and sensor data incorporation
• AI/ML Analytics: Machine learning for pattern detection
• Patient-Reported Outcomes: PRO and ePRO integration
• Genomic Data Linkage: Genetic data integration opportunities
• Multi-Omics: Complementary biological data integration

Clinical Research Examples from THIN

Published Research Using THIN in Neurodegeneration

Alzheimer's Disease:

• "Prescribing patterns in Alzheimer's disease: A THIN database study" (Age and Ageing, 2019)[@prescribing_patterns_ad]
• "Comorbidity patterns in Alzheimer's disease" (BMC Geriatrics, 2022)[@comorbidity_ad]
• "Drug exposure and Alzheimer's disease risk" (J Alzheimer's Disease, 2020)[@drug_exposure_ad]
• "Cardiovascular risk factors and Alzheimer's disease" (JNNP, 2020)[@cardiovascular_ad]

• "Incidence and prevalence of Parkinson's disease using THIN" (Parkinsonism Relat Disord, 2020)[@parkinson_thin]
• "Treatment patterns in early Parkinson's disease" (Movement Disorders, 2021)[@treatment_patterns]

• "Kidney function and cognitive decline" (Alzheimer's & Dementia, 2021)[@egfr_cognitive]
• "Healthcare resource utilization in dementia" (PLOS ONE, 2022)[@healthcare_costs]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Target disease for RWE research
• [Parkinson's Disease](/diseases/parkinsons-disease) — Another neurodegenerative focus
• [Dementia](/diseases/alzheimers-disease) — Disease category served
• [Real-World Evidence](/mechanisms/real-world-evidence) — Type of data Cegedim provides
• [THIN Database](/companies/thin-database) — Primary care EHR database
• [IQVIA](/companies/iqvia) — Major competitor in health data
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Rare tauopathy researched
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Another rare neurodegenerative disorder

External Links

• [Cegedim Corporate Website](https://www.cegedim.com)
• [Cegedim Health Data](https://www.cegedim.com/healthcare-data)
• [THIN Database Information](https://www.cegedim.com/healthcare-data/thin-database)
• [Euronext Paris: CGDM.PA](https://www.euronext.com/en/real-time-stock-quote)
• [LinkedIn: Cegedim](https://www.linkedin.com/company/cegedim)

References